These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
52 related articles for article (PubMed ID: 8165622)
1. The use of active centre acylation to control the pharmacokinetic profile of a recombinant chimaeric plasminogen activator. Wilson S; Cronk DW; Dodd I; Esmail AF; Kalindjian SB; McMurdo L; Browne MJ; Smith RA; Robinson JH Thromb Haemost; 1993 Dec; 70(6):984-8. PubMed ID: 8165622 [TBL] [Abstract][Full Text] [Related]
3. Interaction of a plasmin A-chain/t-PA B-chain hybrid enzyme with plasma inhibitors in vivo and in vitro. Wilson S; Chamberlain P; Dodd I; Esmail A; Robinson JH Thromb Haemost; 1990 Jun; 63(3):459-63. PubMed ID: 1698316 [TBL] [Abstract][Full Text] [Related]
4. Isolation, identification and pharmacokinetic properties of human tissue-type plasminogen activator species: possible localisation of a clearance recognition site. Dodd I; Nunn B; Robinson JH Thromb Haemost; 1988 Jun; 59(3):523-8. PubMed ID: 3142086 [TBL] [Abstract][Full Text] [Related]
5. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138 [TBL] [Abstract][Full Text] [Related]
6. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop. Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954 [TBL] [Abstract][Full Text] [Related]
7. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site. Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727 [TBL] [Abstract][Full Text] [Related]
8. A recombinant, chimeric enzyme with a novel mechanism of action leading to greater potency and selectivity than tissue-type plasminogen activator. Robinson JH; Browne MJ; Carey JE; Chamberlain PD; Chapman CG; Cronk DW; Dodd I; Entwisle C; Esmail AF; Kalindjian SB Circulation; 1992 Aug; 86(2):548-52. PubMed ID: 1638720 [TBL] [Abstract][Full Text] [Related]
9. Expression and characterization of clustered charge-to-alanine mutants of low M(r) single-chain urokinase-type plasminogen activator. Ueshima S; Holvoet P; Lijnen HR; Nelles L; Seghers V; Collen D Thromb Haemost; 1994 Jan; 71(1):134-40. PubMed ID: 8165632 [TBL] [Abstract][Full Text] [Related]
10. The role of the low-density lipoprotein receptor-related protein (LRP) in the plasma clearance and liver uptake of recombinant single-chain urokinase-type plasminogen activator in rats. van der Kaaden ME; Rijken DC; Kruijt JK; van Berkel TJ; Kuiper J Thromb Haemost; 1997 Apr; 77(4):710-7. PubMed ID: 9134648 [TBL] [Abstract][Full Text] [Related]
11. A hybrid plasminogen activator binds to the u-PA receptor and has a reduced thrombolytic potency in vivo. Asselbergs FA; Bürgi R; Hamerman J; Heim J; van Oostrum J; Agnelli G Thromb Haemost; 1993 Jan; 69(1):50-5. PubMed ID: 8383359 [TBL] [Abstract][Full Text] [Related]
12. [The fibrinolytic system and its activators]. Seifried E Z Gesamte Inn Med; 1993; 48(6-7):272-82. PubMed ID: 8333223 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of plasmatic plasminogen activator in rabbits. González Rey JR; Cuevas Valdespino M; Cardona M; Díaz A; Gongora C; Pérez B; Sánchez J Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):171-6. PubMed ID: 2459015 [TBL] [Abstract][Full Text] [Related]
17. Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits. Korninger C; Stassen JM; Collen D Thromb Haemost; 1981 Oct; 46(3):658-61. PubMed ID: 7198302 [TBL] [Abstract][Full Text] [Related]
18. Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. Martin U; Sponer G; Strein K Drug Metab Dispos; 1993; 21(2):236-41. PubMed ID: 8097691 [TBL] [Abstract][Full Text] [Related]
19. The 2.3 A crystal structure of the catalytic domain of recombinant two-chain human tissue-type plasminogen activator. Lamba D; Bauer M; Huber R; Fischer S; Rudolph R; Kohnert U; Bode W J Mol Biol; 1996 Apr; 258(1):117-35. PubMed ID: 8613982 [TBL] [Abstract][Full Text] [Related]
20. Functional effects of kringle 2 glycosylation in a hybrid plasminogen activator. Asselbergs FA; Bürgi R; van Oostrum J Blood Coagul Fibrinolysis; 1993 Feb; 4(1):27-33. PubMed ID: 8384498 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]